Patents by Inventor Mathias Norrman
Mathias Norrman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240141011Abstract: The present invention is in the therapeutic field of drugs for medical conditions relating to diabetes. More specifically the invention relates to insulin analogues of human insulin. The invention provides pharmaceutical compositions comprising such insulin analogues and the uses if the such analogues for the treatment or prevention of medical conditions relating to diabetes.Type: ApplicationFiled: December 15, 2023Publication date: May 2, 2024Inventors: Frantisek Hubalek, Mathias Norrman, Helle Birk Olsen, Peter Madsen, Thomas Boerglum Kjeldsen, Jeppe Sturis
-
Publication number: 20240067944Abstract: The present invention provides ISVD polypeptide derivatives capable of binding coagulation Factor IX(a) and Factor X(a) which are highly potent and provide a sufficiently long half-life such to allow for effective subcutaneous—as well as peroral administration. The ISVD polypeptides derivatives disclosed herein are thus suitable for treatment of haemophilia A, haemophilia A with inhibitors and acquired haemophilia A by various routes of administration including subcutaneous and peroral administration.Type: ApplicationFiled: July 7, 2023Publication date: February 29, 2024Applicant: Novo Nordisk A/SInventors: Andreas Vegge, Daniele Granata, Eva Johansson, Jais Rose Bjelke, Jacob Lund, Philip Jonas Sassene, Per J. Greisen, Thomas Egebjerg, Evelyn De Tavernier, Soren Steffensen, Marie-Ange Buyse, Frantisek Hubalek, Simone Fulle, Mathias Norrman
-
Publication number: 20230192801Abstract: The present invention is in the therapeutic field of drugs for medical conditions relating to diabetes. More specifically the invention relates to insulin analogues of human insulin. The invention provides pharmaceutical compositions comprising such insulin analogues and the uses if the such analogues for the treatment or prevention of medical conditions relating to diabetes.Type: ApplicationFiled: October 6, 2022Publication date: June 22, 2023Applicants: Novo Nordisk A/S, Novo Nordisk A/SInventors: Frantisek Hubalek, Mathias Norrman, Helle Birk Olsen, Peter Madsen, Thomas Boerglum Kjeldsen, Jeppe Sturis
-
Patent number: 11649269Abstract: The present invention relates to novel covalently linked bi-functional fusion proteins comprising insulin and EGF(A) analogues or derivatives thereof, and their pharmaceutical use. Furthermore, the invention relates to pharmaceutical compositions comprising such bi-functional compounds, and to the use of such compounds for the treatment or prevention of medical conditions relating to diabetes and dyslipidaemia associated with diabetes.Type: GrantFiled: October 4, 2019Date of Patent: May 16, 2023Assignee: Novo Nordisk A/SInventors: Martin Werner Borchsenius Muenzel, Susanne Hostrup, Gro Klitgaard Povlsen, Mathias Norrman, Thomas Boerglum Kjeldsen, Claudia Ulrich Hjoerringgaard, Peter Madsen
-
Patent number: 11498951Abstract: The present invention is in the therapeutic field of drugs for medical conditions relating to diabetes. More specifically the invention relates to insulin analogues of human insulin. The invention provides pharmaceutical compositions comprising such insulin analogues and the uses if the such analogues for the treatment or prevention of medical conditions relating to diabetes.Type: GrantFiled: December 10, 2020Date of Patent: November 15, 2022Assignee: Novo Nordisk A/SInventors: Frantisek Hubalek, Mathias Norrman, Helle Birk Olsen, Peter Madsen, Thomas Boerglum Kjeldsen, Jeppe Sturis
-
Publication number: 20220202909Abstract: The present invention is in the field of pharmaceutical compositions for the treatment of medical conditions relating to diabetes. More specifically the invention provides pharmaceutical compositions comprising a long-acting acylated derivative of a human insulin analogue, and to the medical use of such compositions for basal insulin administration therapy.Type: ApplicationFiled: March 11, 2022Publication date: June 30, 2022Inventors: Mathias Norrman, Susanne Hostrup, Dorte Bjerre Steensgaard, Holger Martin Strauss, Rosa Rebecca Erritzoee Hansen, Svend Havelund, Morten Schlein, Jesper Soendergaard Pedersen
-
Patent number: 11352406Abstract: The present invention is in the therapeutic fields of drugs for medical conditions relating to diabetes. More specifically the invention relates to novel acylated derivatives of human insulin analogues. The invention also provides pharmaceutical compositions comprising such insulin derivatives, and relates to the use of such derivatives for the treatment or prevention of medical conditions relating to diabetes.Type: GrantFiled: August 24, 2016Date of Patent: June 7, 2022Assignee: Novo Nordisk A/SInventors: Peter Madsen, Anthony Murray, Martin Muenzel, Claudia Ulrich Hjoerringgaard, Susanne Hostrup, Tine Glendorf, Mathias Norrman, Christian Fledelius
-
Publication number: 20220009989Abstract: The present invention relates to novel covalently linked bi-functional fusion proteins comprising insulin and EGF(A) analogues or derivatives thereof, and their pharmaceutical use. Furthermore, the invention relates to pharmaceutical compositions comprising such bi-functional compounds, and to the use of such compounds for the treatment or prevention of medical conditions relating to diabetes and dyslipidaemia associated with diabetes.Type: ApplicationFiled: October 4, 2019Publication date: January 13, 2022Inventors: Martin Werner Borchsenius Muenzel, Susanne Hostrup, Gro Klitgaard Povlsen, Mathias Norrman, Thomas Boerglum Kjeldsen, Claudia Ulrich Hjoerringgaard, Peter Madsen
-
Publication number: 20210179685Abstract: The present invention is in the therapeutic field of drugs for medical conditions relating to diabetes. More specifically the invention relates to insulin analogues of human insulin. The invention provides pharmaceutical compositions comprising such insulin analogues and the uses if the such analogues for the treatment or prevention of medical conditions relating to diabetes.Type: ApplicationFiled: December 10, 2020Publication date: June 17, 2021Inventors: Frantisek Hubalek, Mathias Norrman, Helle Birk Olsen, Peter Madsen, Thomas Boerglum Kjeldsen
-
Publication number: 20200384088Abstract: The present invention is in the field of pharmaceutical compositions for the treatment of medical conditions relating to diabetes. More specifically the invention provides pharmaceutical compositions comprising a long-acting acylated derivative of a human insulin analogue, and to the medical use of such compositions for basal insulin administration therapy.Type: ApplicationFiled: August 4, 2020Publication date: December 10, 2020Inventors: Mathias Norrman, Susanne Hostrup, Dorte Bjerre Steensgaard, Holger Martin Strauss, Rosa Rebecca Erritzoee Hansen, Svend Havelund, Morten Schlein, Jesper Soendergaard Pedersen
-
Publication number: 20200283493Abstract: The present invention is in the therapeutic fields of drugs for medical conditions relating to diabetes. More specifically the invention relates to novel acylated derivatives of human insulin analogues. The invention also provides pharmaceutical compositions comprising such insulin derivatives, and relates to the use of such derivatives for the treatment or prevention of medical conditions relating to diabetes.Type: ApplicationFiled: March 25, 2020Publication date: September 10, 2020Inventors: Peter Madsen, Martin Muenzel, Claudia Ulrich Hjoerringgaard, Susanne Hostrup, Tine Glendorf, Mathias Norrman, Christian Fledelius
-
Patent number: 10596231Abstract: The present invention is in the field of pharmaceutical compositions for the treatment of medical conditions relating to diabetes. More specifically the invention provides pharmaceutical compositions comprising a long-acting acylated derivative of a human insulin analogue, and to the medical use of such compositions for basal insulin administration therapy.Type: GrantFiled: February 20, 2019Date of Patent: March 24, 2020Assignee: Novo Nordisk A/SInventors: Mathias Norrman, Susanne Hostrup, Dorte Bjerre Steensgaard, Holger Martin Strauss, Rosa Rebecca Erritzoee Hansen, Svend Havelund, Morten Schlein, Jesper Soendergaard Pedersen
-
Publication number: 20190183979Abstract: The present invention is in the field of pharmaceutical compositions for the treatment of medical conditions relating to diabetes. More specifically the invention provides pharmaceutical compositions comprising a long-acting acylated derivative of a human insulin analogue, and to the medical use of such compositions for basal insulin administration therapy.Type: ApplicationFiled: February 20, 2019Publication date: June 20, 2019Inventors: Mathias Norrman, Susanne Hostrup, Dorte Bjerre Steensgaard, Holger Martin Strauss, Rosa Rebecca Erritzoee Hansen, Svend Havelund, Morten Schlein, Jesper Soendergaard Pedersen
-
Patent number: 10265385Abstract: The present invention is in the field of pharmaceutical compositions for the treatment of medical conditions relating to diabetes. More specifically the invention provides pharmaceutical compositions comprising a long-acting acylated derivative of a human insulin analog, and to the medical use of such compositions for basal insulin administration therapy.Type: GrantFiled: June 29, 2018Date of Patent: April 23, 2019Assignee: Novo Nordisk A/SInventors: Mathias Norrman, Susanne Hostrup, Dorte Bjerre Steensgaard, Holger Martin Strauss, Rosa Rebecca Erritzoee Hansen, Svend Havelund, Morten Schlein, Jesper Soendergaard Pedersen
-
Publication number: 20190010206Abstract: The present invention is in the therapeutic fields of drugs for medical conditions relating to diabetes. More specifically the invention relates to novel acylated derivatives of human insulin analogues. The invention also provides pharmaceutical compositions comprising such insulin derivatives, and relates to the use of such derivatives for the treatment or prevention of medical conditions relating to diabetes.Type: ApplicationFiled: August 24, 2016Publication date: January 10, 2019Inventors: Peter Madsen, Martin Muenzel, Claudia Ulrich Hjoerringgaard, Susanne Hostrup, Tine Glendorf, Mathias Norrman, Christian Fledelius
-
Publication number: 20180303908Abstract: The present invention is in the field of pharmaceutical compositions for the treatment of medical conditions relating to diabetes. More specifically the invention provides pharmaceutical compositions comprising a long-acting acylated derivative of a human insulin analogue, and to the medical use of such compositions for basal insulin administration therapy.Type: ApplicationFiled: June 29, 2018Publication date: October 25, 2018Inventors: Mathias Norrman, Susanne Hostrup, Dorte Bjerre Steensgaard, Holger Martin Strauss, Rosa Rebecca Erritzoee Hansen, Hansen, Svend Havelund, Morten Schlein, Jesper Soendergaard Pedersen
-
Publication number: 20180305431Abstract: The present invention is in the therapeutic fields of drugs for medical conditions relating to diabetes. More specifically the invention relates to novel acylated derivatives of human insulin analogues. The invention also provides pharmaceutical compositions comprising such insulin derivatives, and relates to the use of such derivatives for the treatment or prevention of medical conditions relating to diabetes.Type: ApplicationFiled: August 24, 2016Publication date: October 25, 2018Inventors: Peter Madsen, Anthony Murray, Martin Muenzel, Claudia Ulrich Hjoerringgaard, Susanne Hostrup, Tine Glendorf, Mathias Norrman, Christian Fledelius
-
Publication number: 20180169190Abstract: The present invention is in the field of pharmaceutical compositions for the treatment of medical conditions relating to diabetes. More specifically the invention provides pharmaceutical compositions comprising a long-acting acylated derivative of a human insulin analogue, and to the medical use of such compositions for basal insulin administration therapy.Type: ApplicationFiled: December 15, 2017Publication date: June 21, 2018Inventors: Mathias Norrman, Susanne Hostrup, Dorte Bjerre Steensgaard, Holger Martin Strauss, Rosa Rebecca Erritzoee Hansen, Svend Havelund, Morten Schlein, Jesper Soendergaard Pedersen